$EQ
Equillium, Inc.

2019 Q4 Form 10-K Financial Statement

#000156459020013207 Filed on March 26, 2020

View on sec.gov

Income Statement

Concept 2019 Q4 2019 2018 Q4
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.170M $9.090M $1.710M
YoY Change 26.9% 147.68% 968.75%
% of Gross Profit
Research & Development $5.450M $17.64M $2.520M
YoY Change 116.27% 256.87% 425.0%
% of Gross Profit
Depreciation & Amortization $0.00 $23.00K $10.00K
YoY Change -100.0% 283.33%
% of Gross Profit
Operating Expenses $7.616M $26.73M $4.228M
YoY Change 80.13% 210.24% -760.83%
Operating Profit -$26.73M
YoY Change 210.24%
Interest Expense $20.00K $1.110M -$760.0K
YoY Change -102.63% -123.97% 61.7%
% of Operating Profit
Other Income/Expense, Net $30.00K $1.127M
YoY Change -124.31%
Pretax Income -$7.570M -$23.17M -$4.990M
YoY Change 51.7% 74.85% 349.55%
Income Tax
% Of Pretax Income
Net Earnings -$7.567M -$25.60M -$4.992M
YoY Change 51.58% 93.21% 351.21%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$435.6K -$1.473M -$307.1K
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2019 Q4 2019 2018 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $53.14M $53.14M $65.91M
YoY Change -19.37% -19.37% 827.89%
Cash & Equivalents $13.22M $13.22M $28.51M
Short-Term Investments $39.92M $39.92M $37.41M
Other Short-Term Assets $2.300M $2.290M $1.200M
YoY Change 91.67% 92.44%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $55.43M $55.43M $67.10M
YoY Change -17.39% -17.39% 838.53%
LONG-TERM ASSETS
Property, Plant & Equipment $93.00K $90.00K $64.00K
YoY Change 45.31% 50.0% 2981.37%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $15.00K $20.00K
YoY Change
Total Long-Term Assets $108.0K $110.0K $64.00K
YoY Change 68.75% 83.33% 2981.37%
TOTAL ASSETS
Total Short-Term Assets $55.43M $55.43M $67.10M
Total Long-Term Assets $108.0K $110.0K $64.00K
Total Assets $55.54M $55.54M $67.16M
YoY Change -17.31% -17.3% 839.15%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.873M $1.870M $1.119M
YoY Change 67.38% 66.96% 359.09%
Accrued Expenses $2.010M $2.010M $909.0K
YoY Change 121.12% 120.88% 179.62%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $3.883M $3.880M $2.028M
YoY Change 91.47% 91.13% 256.53%
LONG-TERM LIABILITIES
Long-Term Debt $9.681M $9.680M $0.00
YoY Change -100.0%
Other Long-Term Liabilities $127.0K $130.0K $200.0K
YoY Change -36.5% -35.0% -75.0%
Total Long-Term Liabilities $9.808M $9.810M $200.0K
YoY Change 4804.0% 4805.0% -97.75%
TOTAL LIABILITIES
Total Short-Term Liabilities $3.883M $3.880M $2.028M
Total Long-Term Liabilities $9.808M $9.810M $200.0K
Total Liabilities $13.69M $13.69M $2.228M
YoY Change 514.5% 513.9% -76.31%
SHAREHOLDERS EQUITY
Retained Earnings -$41.11M -$15.51M
YoY Change 165.03% 585.8%
Common Stock $82.94M $80.44M
YoY Change 3.1% 821659.12%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $41.85M $41.85M $64.94M
YoY Change
Total Liabilities & Shareholders Equity $55.54M $55.54M $67.16M
YoY Change -17.31% -17.3% 839.15%

Cashflow Statement

Concept 2019 Q4 2019 2018 Q4
OPERATING ACTIVITIES
Net Income -$7.567M -$25.60M -$4.992M
YoY Change 51.58% 93.21% 351.21%
Depreciation, Depletion And Amortization $0.00 $23.00K $10.00K
YoY Change -100.0% 283.33%
Cash From Operating Activities -$9.030M -$22.95M -$3.830M
YoY Change 135.77% 204.93% 882.05%
INVESTING ACTIVITIES
Capital Expenditures -$10.00K $74.00K $0.00
YoY Change 111.43%
Acquisitions
YoY Change
Other Investing Activities -$5.310M -$2.090M -$37.40M
YoY Change -85.8% -94.41%
Cash From Investing Activities -$5.330M -$2.166M -$37.40M
YoY Change -85.75% -94.21%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net -$156.0K
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -100.0K 9.836M 64.77M
YoY Change -100.15% -85.18% 856.72%
NET CHANGE
Cash From Operating Activities -9.030M -22.95M -3.830M
Cash From Investing Activities -5.330M -2.166M -37.40M
Cash From Financing Activities -100.0K 9.836M 64.77M
Net Change In Cash -14.46M -15.29M 23.54M
YoY Change -161.43% -171.43% 268.97%
FREE CASH FLOW
Cash From Operating Activities -$9.030M -$22.95M -$3.830M
Capital Expenditures -$10.00K $74.00K $0.00
Free Cash Flow -$9.020M -$23.02M -$3.830M
YoY Change 135.51% 204.5% 882.05%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
82938000
CY2019Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
127000
CY2019Q4 us-gaap Liabilities
Liabilities
13691000
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
1000
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
21000
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-41112000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
41848000
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
55539000
CY2017Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
19000
CY2018 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
11000
CY2019 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9087000
CY2019 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
74000
CY2018 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4943000
CY2018 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3672000
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
17425654
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
17425654
CY2019 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
17640000
CY2019 dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
CY2019 dei Entity File Number
EntityFileNumber
001-38692
CY2019 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2019 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
82-1554746
CY2019 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2019 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2019 dei Entity Address Address Line1
EntityAddressAddressLine1
2223 Avenida de la Playa
CY2019 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 105
CY2019 dei Entity Address City Or Town
EntityAddressCityOrTown
La Jolla
CY2019 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2018Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
909000
CY2019 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92037
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3883000
CY2019 dei City Area Code
CityAreaCode
858
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
93000
CY2019 dei Local Phone Number
LocalPhoneNumber
412-5302
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2028000
CY2019Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
9681000
CY2019 dei Document Annual Report
DocumentAnnualReport
true
CY2019 dei Document Transition Report
DocumentTransitionReport
false
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
13219000
CY2019Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
39924000
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2288000
CY2019Q4 us-gaap Assets Current
AssetsCurrent
55431000
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
15000
CY2019Q4 us-gaap Assets
Assets
55539000
CY2018Q4 us-gaap Assets
Assets
67163000
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1873000
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1119000
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2010000
CY2018Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
200000
CY2018Q4 us-gaap Liabilities
Liabilities
2228000
CY2018Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
1000
CY2018Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
80441000
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2018Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
5000
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-15512000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
64935000
CY2019 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1901521
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
67163000
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
17376236
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
17376236
CY2019 us-gaap Operating Expenses
OperatingExpenses
26727000
CY2018 us-gaap Operating Expenses
OperatingExpenses
8615000
CY2019 us-gaap Operating Income Loss
OperatingIncomeLoss
-26727000
CY2018 us-gaap Operating Income Loss
OperatingIncomeLoss
-8615000
CY2019 us-gaap Interest Expense Debt
InterestExpenseDebt
279000
CY2018 us-gaap Interest Expense Debt
InterestExpenseDebt
2558000
CY2018 eq Change In Fair Value Adjustment Of Anti Dilution Right
ChangeInFairValueAdjustmentOfAntiDilutionRight
2417000
CY2019 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1127000
CY2018 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-4635000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-25600000
CY2018 us-gaap Net Income Loss
NetIncomeLoss
-13250000
CY2019 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
44000
CY2018 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
5000
CY2019 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-28000
CY2018 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
5000
CY2019 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-25584000
CY2018 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-13245000
CY2019 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.47
CY2018 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.09
CY2019 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
17378096
CY2018 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
12190245
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
-2252000
CY2018 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
12303000
CY2018 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
18000
CY2018 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
442000
CY2018 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
5000
CY2019 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
42000
CY2019 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
266000
CY2019 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
69000
CY2019 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2252000
CY2019 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
16000
CY2018 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
2123000
CY2019 us-gaap Profit Loss
ProfitLoss
-25600000
CY2018 us-gaap Profit Loss
ProfitLoss
-13250000
CY2019 us-gaap Depreciation And Amortization
DepreciationAndAmortization
23000
CY2018 us-gaap Depreciation And Amortization
DepreciationAndAmortization
6000
CY2019 us-gaap Share Based Compensation
ShareBasedCompensation
2252000
CY2018 us-gaap Share Based Compensation
ShareBasedCompensation
442000
CY2019 us-gaap Straight Line Rent
StraightLineRent
-2000
CY2018 us-gaap Straight Line Rent
StraightLineRent
-1000
CY2018 us-gaap Paid In Kind Interest
PaidInKindInterest
2557000
CY2019 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
382000
CY2019 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
65000
CY2019 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
20000
CY2019 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1115000
CY2018 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1140000
CY2019 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
775000
CY2018 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
843000
CY2019 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1051000
CY2018 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
598000
CY2019 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-22949000
CY2018 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-7526000
CY2019 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
74000
CY2018 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
35000
CY2019 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
54619000
CY2018 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
37399000
CY2019 us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
52527000
CY2019 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2166000
CY2018 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-37434000
CY2018 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
64475000
CY2018 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
1599000
CY2019 us-gaap Proceeds From Debt Net Of Issuance Costs
ProceedsFromDebtNetOfIssuanceCosts
9881000
CY2019 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
-156000
CY2019 eq Proceeds From Exercise Of Stock Options Including Early Exercise
ProceedsFromExerciseOfStockOptionsIncludingEarlyExercise
69000
CY2018 eq Proceeds From Exercise Of Stock Options Including Early Exercise
ProceedsFromExerciseOfStockOptionsIncludingEarlyExercise
291000
CY2019 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
42000
CY2019 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
9836000
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1215000
CY2019Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
39875000
CY2019Q4 eq Accrued Clinical Studies
AccruedClinicalStudies
442000
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
267000
CY2019 us-gaap Interest Paid Net
InterestPaidNet
142000
CY2019 eq Fair Value Of Common Stock Warrants In Connection With Issuance Of Notes Payable
FairValueOfCommonStockWarrantsInConnectionWithIssuanceOfNotesPayable
266000
CY2019 eq Stock Issuance Costs In Accrued Expenses
StockIssuanceCostsInAccruedExpenses
50000
CY2019 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
11000
CY2018 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
33000
CY2018 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
12304000
CY2019 us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of the Company&#8217;s consolidated financial statements requires the Company to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in the consolidated financial statements and accompanying notes. Significant estimates in the Company&#8217;s consolidated financial statements relate to clinical trial accruals and the valuation of equity awards. Management evaluates its estimates on an ongoing basis. Although estimates are based on the Company&#8217;s historical experience, knowledge of current events, and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions. </p>
CY2019 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Concentration of Credit Risk and Off-Balance Sheet Risk</p> <p style="margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments which potentially subject the Company to significant concentration of credit risk consist of cash and cash equivalents and short-term investments. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts, and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. The Company&#8217;s investment policy includes guidelines for the quality of the related institutions and financial instruments and defines allowable investments that the Company may invest in, which the Company believes minimizes the exposure to concentration of credit risk.</p>
CY2019Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
53100000
CY2018 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
420481
CY2018Q4 eq Accrued Clinical Studies
AccruedClinicalStudies
245000
CY2018Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
96000
CY2019Q4 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
39924000
CY2019Q4 eq Accrued Preclinical Studies
AccruedPreclinicalStudies
15000
CY2018Q4 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
37405000
CY2019Q4 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0
CY2019Q4 us-gaap Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
0
CY2019 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
0
CY2018Q4 eq Accrued Preclinical Studies
AccruedPreclinicalStudies
8000
CY2019Q4 us-gaap Interest Payable Current
InterestPayableCurrent
71000
CY2019Q3 us-gaap Line Of Credit Facility Expiration Date1
LineOfCreditFacilityExpirationDate1
2024-06-01
CY2019Q3 us-gaap Warrants Not Settleable In Cash Fair Value Disclosure
WarrantsNotSettleableInCashFairValueDisclosure
300000
CY2019 dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2017-03-16
CY2019 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
0
CY2019Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
55000
CY2019Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
6000
CY2018Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
37400000
CY2018Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
5000
CY2019 us-gaap Other Than Temporary Impairment Losses Investments Portion Recognized In Earnings Net Availableforsale Securities
OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNetAvailableforsaleSecurities
0
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
29000
CY2018Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
6000
CY2019 us-gaap Depreciation
Depreciation
23000
CY2018 us-gaap Depreciation
Depreciation
6000
CY2019 us-gaap Property Plant And Equipment Disposals
PropertyPlantAndEquipmentDisposals
0
CY2018 us-gaap Property Plant And Equipment Disposals
PropertyPlantAndEquipmentDisposals
0
CY2018Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
560000
CY2019Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
354000
CY2019Q4 eq Debt Instrument Carrying Amount Including Unaccreted Liability For Final Payment Fee Maturities Repayments Of Principal In Year Two
DebtInstrumentCarryingAmountIncludingUnaccretedLiabilityForFinalPaymentFeeMaturitiesRepaymentsOfPrincipalInYearTwo
1667000
CY2019Q4 eq Debt Instrument Carrying Amount Including Unaccreted Liability For Final Payment Fee Maturities Repayments Of Principal In Year Three
DebtInstrumentCarryingAmountIncludingUnaccretedLiabilityForFinalPaymentFeeMaturitiesRepaymentsOfPrincipalInYearThree
3333000
CY2019Q4 eq Debt Instrument Carrying Amount Including Unaccreted Liability For Final Payment Fee Maturities Repayments Of Principal In Year Four
DebtInstrumentCarryingAmountIncludingUnaccretedLiabilityForFinalPaymentFeeMaturitiesRepaymentsOfPrincipalInYearFour
3333000
CY2019Q4 eq Debt Instrument Carrying Amount Including Unaccreted Liability For Final Payment Fee Maturities Repayments Of Principal In Year Five
DebtInstrumentCarryingAmountIncludingUnaccretedLiabilityForFinalPaymentFeeMaturitiesRepaymentsOfPrincipalInYearFive
2117000
CY2019Q4 us-gaap Long Term Debt
LongTermDebt
9681000
CY2019Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
9681000
CY2019Q4 eq Debt Instrument Carrying Amount Including Unaccreted Liability For Final Payment Fee
DebtInstrumentCarryingAmountIncludingUnaccretedLiabilityForFinalPaymentFee
10450000
CY2019Q4 eq Unaccreted Liability For Final Payment Fee
UnaccretedLiabilityForFinalPaymentFee
415000
CY2019Q4 us-gaap Share Price
SharePrice
3.38
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.65
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
5.79
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
1439000
CY2019Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
1000
CY2018 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-2783000
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
46000
CY2019 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
69000
CY2018 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
291000
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
3346000
CY2019 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2252000
CY2018 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
442000
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0223
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0283
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.9358
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.8829
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y9M7D
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y10M28D
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00
CY2019 eq Dividends Paid On Common Stock
DividendsPaidOnCommonStock
0
CY2019Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
3218710
CY2018Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
2126877
CY2019 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
200000
CY2018 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
49000
CY2019Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
150000
CY2019Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
74000
CY2019Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
10000
CY2019Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
234000
CY2019 us-gaap Litigation Settlement Expense
LitigationSettlementExpense
0
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-23167000
CY2018 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-13250000
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-2433000
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-25600000
CY2018 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-13250000
CY2019 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
0
CY2018 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
0
CY2019 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0
CY2018 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0
CY2019 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-5376000
CY2019 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
1000
CY2019 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
276000
CY2018 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
38000
CY2019 eq Income Tax Reconciliation Permanent Items
IncomeTaxReconciliationPermanentItems
-104000
CY2018 eq Income Tax Reconciliation Permanent Items
IncomeTaxReconciliationPermanentItems
1256000
CY2019 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
684000
CY2018 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
222000
CY2019 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
5887000
CY2018 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
1711000
CY2019Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
7212000
CY2018Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
2268000
CY2019Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
1227000
CY2018Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
334000
CY2019Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
129000
CY2018Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
185000
CY2019Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
409000
CY2018Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
224000
CY2019Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
8977000
CY2018Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
3011000
CY2019Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
8976000
CY2018Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
3011000
CY2019Q4 us-gaap Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
1000
CY2019Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
1000
CY2019Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2018Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2019 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
6000000
CY2019 eq Operating Loss Carryforwards Expiration Year
OperatingLossCarryforwardsExpirationYear
2037
CY2018Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
27500000
CY2019 us-gaap Operating Loss Carryforwards Limitations On Use
OperatingLossCarryforwardsLimitationsOnUse
Federal net operating losses generated after December 31, 2017 carryover indefinitely and may generally be used to offset up to 80% of future taxable income.
CY2019 eq Tax Credit Carryforward Expiration Year
TaxCreditCarryforwardExpirationYear
2037
CY2019 eq Cumulative Change In Ownership Percentage
CumulativeChangeInOwnershipPercentage
0.50
CY2019 eq Cumulative Change In Ownership Period
CumulativeChangeInOwnershipPeriod
P3Y
CY2018Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
89000
CY2019 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
271000
CY2018 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
81000
CY2019Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
360000
CY2019 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
0
CY2018 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
0
CY2019Q1 us-gaap Operating Expenses
OperatingExpenses
6348000
CY2019Q2 us-gaap Operating Expenses
OperatingExpenses
6439000
CY2019Q3 us-gaap Operating Expenses
OperatingExpenses
6324000
CY2019Q4 us-gaap Operating Expenses
OperatingExpenses
7616000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-5950000
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-6069000
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-6014000
CY2019Q4 us-gaap Net Income Loss
NetIncomeLoss
-7567000
CY2019Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.34
CY2019Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.35
CY2019Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.35
CY2019Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.44
CY2018Q1 us-gaap Operating Expenses
OperatingExpenses
1037000
CY2018Q2 us-gaap Operating Expenses
OperatingExpenses
1125000
CY2018Q3 us-gaap Operating Expenses
OperatingExpenses
2226000
CY2018Q4 us-gaap Operating Expenses
OperatingExpenses
4228000
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-1577000
CY2018Q2 us-gaap Net Income Loss
NetIncomeLoss
-1765000
CY2018Q3 us-gaap Net Income Loss
NetIncomeLoss
-4917000
CY2018Q4 us-gaap Net Income Loss
NetIncomeLoss
-4992000
CY2018Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.15
CY2018Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.16
CY2018Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.44
CY2018Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.31

Files In Submission

Name View Source Status
0001564590-20-013207-index-headers.html Edgar Link pending
0001564590-20-013207-index.html Edgar Link pending
0001564590-20-013207.txt Edgar Link pending
0001564590-20-013207-xbrl.zip Edgar Link pending
eq-10k_20191231.htm Edgar Link pending
eq-20191231.xml Edgar Link completed
eq-20191231.xsd Edgar Link pending
eq-20191231_cal.xml Edgar Link unprocessable
eq-20191231_def.xml Edgar Link unprocessable
eq-20191231_lab.xml Edgar Link unprocessable
eq-20191231_pre.xml Edgar Link unprocessable
eq-ex1015_170.htm Edgar Link pending
eq-ex1018_169.htm Edgar Link pending
eq-ex1019_351.htm Edgar Link pending
eq-ex1020_349.htm Edgar Link pending
eq-ex1021_347.htm Edgar Link pending
eq-ex1022_348.htm Edgar Link pending
eq-ex1023_350.htm Edgar Link pending
eq-ex211_10.htm Edgar Link pending
eq-ex231_6.htm Edgar Link pending
eq-ex311_7.htm Edgar Link pending
eq-ex312_8.htm Edgar Link pending
eq-ex321_9.htm Edgar Link pending
eq-ex44_352.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
ggslcuwjbl1v000001.jpg Edgar Link pending
ggslcuwjbl1v000002.jpg Edgar Link pending
ggslcuwjbl1v000003.jpg Edgar Link pending
ggslcuwjbl1v000004.jpg Edgar Link pending
ggslcuwjbl1v000005.jpg Edgar Link pending
ggslcuwjbl1v000006.jpg Edgar Link pending
ggslcuwjbl1v000007.jpg Edgar Link pending
ggslcuwjbl1v000008.jpg Edgar Link pending
ggslcuwjbl1v000009.jpg Edgar Link pending
ggslcuwjbl1v000010.jpg Edgar Link pending
ggslcuwjbl1v000011.jpg Edgar Link pending
ggslcuwjbl1v000012.jpg Edgar Link pending
ggslcuwjbl1v000013.jpg Edgar Link pending
ggslcuwjbl1v000014.jpg Edgar Link pending
ggslcuwjbl1v000015.jpg Edgar Link pending
ggslcuwjbl1v000016.jpg Edgar Link pending
ggslcuwjbl1v000017.jpg Edgar Link pending
ggslcuwjbl1v000018.jpg Edgar Link pending
ggslcuwjbl1v000019.jpg Edgar Link pending
grswbb5ns5po000001.jpg Edgar Link pending
gtzwcs4ggbxo000001.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending